Ngm Biopharmaceuticals Return on Equity

Ngm Biopharmaceuticals (NGM) currently reports a ROE of -94.07%. That is below the Healthcare sector average of 21.67%. Use the charts on this page to explore Ngm Biopharmaceuticals's ROE history and peer comparisons.

Ngm Biopharmaceuticals's ROE of -94.07% is lower than the Healthcare sector average of 21.67%. That is roughly 534.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Ngm Biopharmaceuticals's current -94.07% should be judged against Healthcare norms (sector average: 21.67%) and against NGM's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -94.07%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.67%. From there, open related valuation or income-statement pages for Ngm Biopharmaceuticals, and consider following NGM for alerts when major investors trade the stock.

Ngm Biopharmaceuticals is classified in the Healthcare sector. On ROE, it currently shows -94.07% versus a sector average near 21.67%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NGM with unrelated industries.